US 12,059,470 B2
Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
David Stover, Los Angeles, CA (US); Dhruba Bharali, Sherman Oaks, CA (US); Bruce A Hay, Niskayuna, NY (US); and Tahmineh Safaie, Yucca Valley, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed on May 8, 2023, as Appl. No. 18/445,174.
Application 18/445,174 is a continuation of application No. 17/300,655, filed on Sep. 10, 2021, granted, now 11,833,209.
Prior Publication US 2024/0082407 A1, Mar. 14, 2024
Int. Cl. A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01)
CPC A61K 47/554 (2017.08) [A61K 47/548 (2017.08); A61K 47/549 (2017.08); A61K 47/6911 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01)] 18 Claims
 
1. A method of treating a subject suffering or diagnosed with cancer comprising,
(i) administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises a PD-1 Prodrug having the following chemical structure

OG Complex Work Unit Chemistry
 and
(ii) a pharmaceutically acceptable salt thereof.